<?xml version='1.0' encoding='utf-8'?>
<document id="29470228"><sentence text="Amiodarone Rifampicin Drug-Drug Interaction Management With Therapeutic Drug Monitoring."><entity charOffset="0-21" id="DDI-PubMed.29470228.s1.e0" text="Amiodarone Rifampicin" /></sentence><sentence text="The authors present a case of a 69-year-old man with arrhythmogenic right ventricular cardiomyopathy controlled with amiodarone and an infected orthopedic prosthesis requiring treatment with rifampicin"><entity charOffset="117-127" id="DDI-PubMed.29470228.s2.e0" text="amiodarone" /><entity charOffset="191-201" id="DDI-PubMed.29470228.s2.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.29470228.s2.e0" e2="DDI-PubMed.29470228.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29470228.s2.e0" e2="DDI-PubMed.29470228.s2.e1" /></sentence><sentence text=" This combination involves a pharmacokinetic drug-drug interaction leading to subtherapeutic drug concentrations of amiodarone and its active metabolite"><entity charOffset="116-126" id="DDI-PubMed.29470228.s3.e0" text="amiodarone" /></sentence><sentence text=" The long half-life of amiodarone and its active metabolite in combination with the late onset and offset of cytochrome P4503A (CYP3A4) induction by rifampicin makes this a challenging drug-drug interaction to cope with in clinical practice"><entity charOffset="23-33" id="DDI-PubMed.29470228.s4.e0" text="amiodarone" /><entity charOffset="149-159" id="DDI-PubMed.29470228.s4.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.29470228.s4.e0" e2="DDI-PubMed.29470228.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29470228.s4.e0" e2="DDI-PubMed.29470228.s4.e1" /></sentence><sentence text=" Before, during, and after rifampicin treatment, the serum concentrations of amiodarone and its active metabolite were measured and the amiodarone dose was adjusted accordingly"><entity charOffset="27-37" id="DDI-PubMed.29470228.s5.e0" text="rifampicin" /><entity charOffset="77-87" id="DDI-PubMed.29470228.s5.e1" text="amiodarone" /><entity charOffset="136-146" id="DDI-PubMed.29470228.s5.e2" text="amiodarone" /><pair ddi="false" e1="DDI-PubMed.29470228.s5.e0" e2="DDI-PubMed.29470228.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29470228.s5.e0" e2="DDI-PubMed.29470228.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29470228.s5.e0" e2="DDI-PubMed.29470228.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29470228.s5.e1" e2="DDI-PubMed.29470228.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29470228.s5.e1" e2="DDI-PubMed.29470228.s5.e2" /></sentence><sentence text=" The amiodarone dose required to maintain effective concentrations was 450% of the initial dose"><entity charOffset="5-15" id="DDI-PubMed.29470228.s6.e0" text="amiodarone" /></sentence><sentence text=" The drug-drug interaction between amiodarone and rifampicin is relevant, both clinically and pharmacokinetically, and can be managed by dose adjustments of amiodarone based on serum concentrations"><entity charOffset="35-45" id="DDI-PubMed.29470228.s7.e0" text="amiodarone" /><entity charOffset="50-60" id="DDI-PubMed.29470228.s7.e1" text="rifampicin" /><entity charOffset="157-167" id="DDI-PubMed.29470228.s7.e2" text="amiodarone" /><pair ddi="false" e1="DDI-PubMed.29470228.s7.e0" e2="DDI-PubMed.29470228.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29470228.s7.e0" e2="DDI-PubMed.29470228.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29470228.s7.e0" e2="DDI-PubMed.29470228.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29470228.s7.e1" e2="DDI-PubMed.29470228.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29470228.s7.e1" e2="DDI-PubMed.29470228.s7.e2" /></sentence><sentence text="" /></document>